- |||||||||| Rituxan (rituximab) / Roche, Biogen, TJC4 - I / Mab
TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5798; Conclusion In summary, TJC4 is a next generation therapeutic anti-CD47 antibody that is devoid of the hematological liabilities while maintaining anti-tumor efficacy. These attributes of TJC4 differentiate it from other CD47 targeting agents currently in clinical evaluation.
|